Identity
Servicio Murciano de Salud - Junta de Compras
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €112.7M | |
| 2025 | €165.7M | |
| 2024 | €246.6M | |
| 2023 | €125.8M | |
| 2022 | €94.4M | |
| 2021 | €85.4M | |
| 2020 | €85.9M |
Main markets · 2024 – 31 Oct 2026
- 85% Pharmaceuticals CPV 336
- 11% Medical equipment CPV 331
- 3% Electricity and energy CPV 093
- 1% rest
In figures
Volume
Between 2020 and 2026 it awarded €917M in 2,747 awards to 357 suppliers.
Price
In 2024–2026, its median competitive discount was 20.5%; the middle half between 7.8% and 36.3% (326 comparable awards).
Competition
In 2024–2026, 58.0% of its 919 awards had a single bidder.
What it buys
In 2024–2026, what it bought most by value was pharmaceuticals (85%), medical equipment (11%) and electricity and energy (3%).
Who it buys from
Its main suppliers. 2024 – 31 Oct 2026
Each curve is one award; its height, the amount awarded.
Top suppliers: Sanofi Aventis, S.A. · Glaxosmithkline, S.A. · Endesa Energía, S.A.U.
At what price it awards
The discount at which it awards in competition, year by year. 2024 – 31 Oct 2026
In competition: two or more bidders, or no published count in a procedure open to competition. Methodology →
Median 20.5% · typical range 7.8%–36.3% (the middle half: 25th–75th percentiles) · 326 awards (one per lot), 2024–2026
Discount on the tender budget, excluding VAT · Source: official data, national and regional coverage. Methodology →
25 awards published at the tender budget are not included in the discount figures: the published amount equals the budget and does not reflect the actual bid.
Comparable awards only: competitive, excluding minor contracts and framework agreements. Methodology
Median 20.0%
2024 – 31 Oct 2026
Chart, range and awards in the reportDetails in the report
Median 26.9%
2024 – 31 Oct 2026
Chart, range and awards in the reportDetails in the report
Median 11.5%
2024 – 31 Oct 2026
Chart, range and awards in the reportDetails in the report
Discounts calculated on awards above the minor-contract threshold.
What the report includes
For each sector, the full chart, the typical range and all its awards. Including, among others:
Plus the complete register of its awards in Excel (2024 – Oct 2026). These are the 5 most recent:
| Date | Sector | Winner | Budget | Discount % | Bidders |
|---|---|---|---|---|---|
| 25/10/2026 | 336 · Pharmaceuticals | Ever Pharma Therapeutics Spain, S.L. | 291,200€ | 44.0% | 4 |
| 25/10/2026 | 336 · Pharmaceuticals | Altan Pharmaceuticals, S.A.U. | 112,000€ | 11.4% | 2 |
| 25/10/2026 | 336 · Pharmaceuticals | Laboratorios Normon, S.A. | 90,000€ | 16.7% | 2 |
| 25/10/2026 | 336 · Pharmaceuticals | Merck Sharp & Dohme de España, S.A. | 80,500€ | 28.9% | 2 |
| 22/10/2026 | 331 · Medical equipment | Bausch & Lomb, S.A. | 2,440,000€ | 1.3% | 4 |
How it awards
How many bidders it awards against, and by which procedure. 2024 – 31 Oct 2026
100% of its awards publish the number of bidders
What it buys
Which categories it spends in. 2024 – 31 Oct 2026
| Category (CPV) | Value | Awards |
|---|---|---|
| 336 · Pharmaceutical products | €448M | 537 |
| 331 · Medical equipments | €56.7M | 358 |
| 093 · Electricity, heating, solar and nuclear energy | €16.6M | 1 |
| 330 · Medical equipments, pharmaceuticals and personal care products | €2.88M | 22 |
| 384 · Instruments for checking physical characteristics | €993k | 1 |
Recent awards
The last 20 published awards, unfiltered.
| Date | Winner | Bidders | Value |
|---|---|---|---|
| 29/10/2026 | Novartis Farmaceutica, S.A. | Single bidder | €46.9k |
| 29/10/2026 | Novartis Farmaceutica, S.A. | Single bidder | €384k |
| 29/10/2026 | Pierre Fabre Ibérica S.A. | Single bidder | €1.20M |
| 29/10/2026 | Pierre Fabre Ibérica S.A. | Single bidder | €361k |
| 29/10/2026 | Biogen Spain, S.L. | Single bidder | €711k |
| 29/10/2026 | Pierre Fabre Ibérica S.A. | Single bidder | €542k |
| 26/10/2026 | Ucb Pharma, S.A. | Single bidder | €1.68M |
| 26/10/2026 | Ucb Pharma, S.A. | Single bidder | €92.0k |
| 26/10/2026 | Ucb Pharma, S.A. | Single bidder | €184k |
| 26/10/2026 | Ucb Pharma, S.A. | Single bidder | €318k |
| 26/10/2026 | Ucb Pharma, S.A. | Single bidder | €5.35M |
| 26/10/2026 | Ucb Pharma, S.A. | Single bidder | €202k |
| 25/10/2026 | Laboratorios Normon, S.A. | Competitive · 2 | €75.0k |
| 25/10/2026 | Merck Sharp & Dohme de España, S.A. | Competitive · 2 | €57.3k |
| 25/10/2026 | Altan Pharmaceuticals, S.A.U. | Competitive · 2 | €99.2k |
| 25/10/2026 | Laboratorio Stada, S.L. | Competitive · 4 | €393k |
| 25/10/2026 | Ever Pharma Therapeutics Spain, S.L. | Competitive · 4 | €163k |
| 25/10/2026 | Sandoz Farmaceutica | Competitive · 9 | €34.7k |
| 25/10/2026 | Laboratorios Normon, S.A. | Single bidder | €43.2k |
| 25/10/2026 | Teva Pharma, S.L.U. | Competitive · 4 | €1.04M |
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage